PepLogix Review: 73 Bioviridian COAs the Storefront Never Shows You, Pricing, and Caveats
An independent PepLogix review: 73 Bioviridian certificates recovered from unlabelled product attachments, pricing coverage, four dated sales, and the evidence limits.
PepLogix is now a curated vendor on PeptideBenchmark. The strongest reason is a tension worth stating plainly: the vendor publishes more independently confirmable laboratory evidence than its own storefront lets a visitor see. No product description mentions testing, and the certificate index at /coa-library/ requires an account — yet every certificate PepLogix attaches to a public product listing resolves at the issuing laboratory’s own domain, where anyone can check it.
That does not turn “has a COA” into a product-safety endorsement, and a recovered certificate says nothing about the vial a reader receives. This review separates what the laboratory publishes from what PeptideBenchmark could not observe.
Reviewed July 30, 2026. PeptideBenchmark has no affiliate, coupon, sponsorship, or paid-placement relationship with PepLogix. Every certificate here came from public endpoints; the vendor’s account-gated pages and certificate index were not accessed. The vendor sells research-use-only products; this is an evidence and commercial-transparency review, not human-use guidance or medical advice.
The short version
The public catalog exposed 96 distinct products across 113 purchasable rows. After format, dosage-unit, and mg-normalization checks, 73 rows across 56 products were comparable enough to publish, from $50 to $750.
The testing evidence had to be recovered rather than read. Zero of the 113 rows carried a certificate callout, a linked PDF, or any testing language. The certificates are present only as unlabelled PDF attachments in the product-image data, which no page text identifies as certificates. PB located each one and read the image-only PDF by OCR: 74 uploads carrying 73 distinct certificates, since one code is printed on two of them.
Every document is a Bioviridian Inc. report bearing a Web Verification Code the laboratory hosts itself, and all 73 distinct codes — covering every one of the 74 uploads — resolved to a lab-hosted document at bioviridians.com/coas/<code>.pdf, the path the Bioviridian lookup itself checks, on July 30, 2026. A fabricated code returned nothing on the same day, so the check separates a real code from an invented one.
The limits are equally concrete. No lot or batch identifier appears anywhere. 19 of the 96 products carry no attributable certificate — all of them capsules or a serum. None of the 74 documents PB read reports a sterility result. And PB could not read shipping or return terms anonymously.
Laboratory-hosted resolution on every discovered code is a strong, checkable signal, and the certificates name the vendor themselves rather than relying on a logo. The offsetting limits are real: no lot numbers, no sterility result on any document PB read, roughly 35% of the purchasable rows outside per-mg comparison, unreadable commercial terms, and an evidence chain resting on one laboratory host.
What we found in the catalog
| Catalog result | Count | PB treatment |
|---|---|---|
| Distinct public products | 96 | Full Store API surface at capture; a same-day COA pass saw 97, the extra being ARA-290 – 20mg |
| Purchasable rows behind them | 113 | Eight pages carry two to four sizes |
| Comparable vial rows | 73 | Published to Pricing and Stack Builder, across 56 products |
| Deferred formats | 14 | Capsules, serums, a nasal spray, one pack with no stated strength |
| Out-of-scope records | 26 | Capsules, IU-dosed HCG vials, non-peptide injectables, topicals |
| Eligible rows not published | 0 | Nothing comparable was left behind |
The exclusions matter more than the headline. 40 of the 113 rows — about 35% — stay off the per-mg board: 29 capsule products, five topicals and serums, a NAD+ nasal spray, the 5,000 iu and 10,000 iu HCG vials, two non-peptide injectables, and one pack with no stated strength. A capsule and a vial do not share a price basis, and an IU-dosed product has no honest mg denominator. A large storefront count should not become a large comparison count.
All 73 published rows are vials with one exact price — no ranges, no “from $X” placeholders. But only 29 are exact single-compound comparisons: 44 are vendor-aligned, and 20 of those are blends whose milligram total counts the lead compound only. “BPC Wolverine + KPV – 10mg / 10mg / 10mg” is stored as 10 mg though the vial holds 30 mg of actives. Their price per milligram is therefore not a like-for-like number against a single-compound vial, and a reader comparing a blend to a plain vial should know that before drawing a conclusion.
Board prices are the vendor’s standing prices; a sale is recorded separately with the date it was seen.
House codes make price comparison harder than it should be
PepLogix sells its GLP compounds under house abbreviations — Reta (GLP-3), Tirz (GLP-2), Sema (GLP-1) — across 5 mg to 60 mg listings plus reconstituted and BPC-157 variants. A shopper searching the full compound name will not match those titles.
These tags are also pharmacologically wrong, not merely nonstandard: tirzepatide is not a GLP-2 agonist and retatrutide is not a GLP-3 agonist — GLP-2 is a distinct hormone with its own approved drug. PB records the standard identity and does not carry the vendor’s receptor labels onto the board.
The certificates give the game away, which is the useful part: the attached documents name the compound in full — RETATRUTIDE-10ml.pdf, TIRZEPATIDE-60mg-RECON-1.pdf — where the title never does. PB maps each row to the standard peptide identity so the board stays searchable by the real name.
The multi-vial packs split on the same problem. Four Tirz four-vial packs state pack totals in the title — 10 mg, 20 mg, 30 mg, 40 mg — so they normalize cleanly. The Reta pack states neither a per-vial strength nor a total, so it is deferred: dividing its price by an unknown milligram count would invent a number.
The certificate library the storefront does not show
The vendor’s certificate index is account-gated, so it cannot be cited as public evidence and PB neither treats it as such nor accessed it. No product page links a certificate and no product text mentions testing: on the storefront alone, a visitor sees a catalog with no testing surface at all.
The evidence is there anyway, attached to public listings as documents. PeptideBenchmark’s pass:
- enumerates every public catalog record and its attached documents;
- locates each certificate document attached to a listing, even where no page text links it;
- reads the image-only PDF by OCR, then re-reads ambiguous digits;
- deduplicates uploads printing the same verification code;
- extracts laboratory, compound, quantity, purity, panels, and dates the document supports;
- resolves each printed code at the laboratory’s host, against a fabricated-code control; and
- relates each certificate to the product that carried it, preserving any that match none of them.
That produced 74 documents, 73 distinct certificates, and 79 product-certificate pairings, since five documents each cover two products. OCR succeeded on 74 of 74. Browse the PepLogix COA records.
What the laboratory check establishes
Every document names Bioviridian Inc. as issuer and PepLogix on its face, so attribution is stated by the laboratory rather than inferred by PB from a logo or a layout. Each printed code returns a document from the laboratory’s own host; an invented one does not. That is a provider-verification lane rather than a vendor-hosted copy of a document.
What it does not establish
A resolving code proves the laboratory publishes a document under that code. PB did not download the lab’s file or compare it byte-for-byte against the vendor’s upload, so the check confirms the code is real — not that the two documents are identical. It also does not prove the document describes the vial in a reader’s package, because no PepLogix certificate carries a lot or batch number. Nor is it monitored: PB records a dated check made July 30, 2026, not continued liveness.
Panel coverage: four fields everywhere, one gap, one absence
The reports go deeper than a bare purity number. Across the 74 documents, identity, endotoxin, and net content appear on 74 of 74; a purity panel is present on 74 of 74 (one, COA6190, prints no legible figure); and heavy metals on 73 of 74 — the exception being COA3671, the 60 mg reconstituted tirzepatide report.
None of the 74 documents PB read reports a sterility result, and these fields do not substitute for one another. Identity does not establish purity. HPLC purity does not establish sterility. An endotoxin result does not establish heavy-metals content. One report’s panels never propagate to another product’s report.
73 of 74 documents print a readable purity figure. As printed, they run 99.6% to 99.9% (mean ≈ 99.8%). These are figures reported for the samples the laboratory received, read from images — they are not a measured property of any unit PepLogix ships, and no certificate ties to a lot. The gap is COA6190, the retatrutide report (RETATRUTIDE-10ml.pdf) attached to the strength-less Reta (GLP-3) page.
Two caveats: 12 of the 73 readable purities were recovered only after PB re-read digits the first OCR pass rotated, and every one of these numbers is a reading of an image, so the laboratory-hosted copy is the authority for any specific purchase. Dates, unlike lot numbers, are present — 74 of 74 record a sample-received date and an issue date, though none states an assay date.
Nothing is preserved, and coverage is not universal
The certificates are product-generic — zero lot numbers, zero batch codes — so the strongest available claim is that a named sample of that product was tested and reported. PeptideBenchmark has also preserved no copies. All 73 archive records are source-only references to the laboratory host, with no stored bytes and no fingerprint. If that host changes or removes a file, the evidence goes with it.
Coverage is incomplete too: 19 of the 96 products have no attributable certificate — all of them capsules or a serum, and every vial on the comparison board carries one. (The evidence panel counts 97 Store API products and 78 with certificates; the extra product is the ARA-290 page below.) One report — COA6152, ARA-290 20 mg — resolves at the laboratory and names a PepLogix product page, but that page is absent from the 96-product catalog snapshot PB captured the same day, so it is not counted against current catalog coverage.
Pricing: one discount lane, four sale items, one comparable change
PepLogix runs one discount mechanic. PB checked for a sitewide percentage, a bundle builder, quantity tiers, and a public coupon or referral code, and found none. What exists is per-item sales, four of them on July 30, 2026:
- KPV Capsules 500 mcg, $125 to $100;
- GHK-Cu Capsules 2 mg, $150 to $100;
- TB-500 Capsules 500 mcg, $150 to $100; and
- VIP 10 mg, $100 to $75.
Only one reaches the comparison board: the three capsule products sit outside per-mg comparison, so VIP 10 mg is the sole sale that changes a tracked price, and “four active discounts” would overstate the effect fourfold.
These are the vendor’s own promotions, dated to this review rather than standing offers; PeptideBenchmark has no PepLogix code and earns nothing if a reader uses them. Standing prices remain the basis on Pricing and in the Stack Builder.
Shipping and returns could not be read
An anonymous request to a PepLogix product page redirected to the storefront’s account page. PB captured no shipping cost, carrier, cutoff time, free-shipping threshold, or refund term, and publishes none. It is an unusual gap: the testing is confirmable at a third party while the commercial terms are invisible without an account.
Why PepLogix is curated
Curated means PB has enough inspectable material to maintain a structured, challengeable record. It is not an endorsement and it is not a guarantee. For PepLogix, that work includes:
- anonymous catalog discovery at 96 products and 113 rows;
- exact standing prices, with no ranges, on every published row;
- documented reasons for all 40 excluded rows;
- certificate recovery from unlabelled attachments no page text links;
- OCR reading of 74 image-only PDFs with a digit re-read pass;
- laboratory-side resolution of every printed code, against a fabricated-code control run the same day;
- panel, purity, and date extraction kept per document rather than propagated;
- dated capture of the vendor’s four per-item sales; and
- automated re-checks that flag the record for review if the catalog or evidence surface changes.
Scale keeps a good number from reading as a great one. 73 provider-verified certificates sits just above the curated median of 30 provider-verified documents and far below the deepest at 292; measured against total archived corpus, 73 is close to the curated median of 70 and ranks 35th of 72. A Strong trust band describes 43 of the 72 curated vendors, and the 7.94 evidence score ranks 15th of the 36 curated vendors carrying one. Those are baseline markers, not distinctions — how the vendor benchmark works explains what they measure.
The live PepLogix profile carries the current score, trust band, pricing coverage, and evidence links.
Bottom line
PepLogix’s strongest signal is that its evidence does not depend on trusting PepLogix. Each certificate prints a code the issuing laboratory hosts and resolves, each names the vendor on its face, and a fabricated code fails the same check — so a reader can confirm the document exists without accepting a vendor claim. Keeping that behind an account gate, with no product copy mentioning testing, does not weaken the certificates — but it does mean a shopper on the storefront sees no testing at all, which is a real transparency gap even where the evidence holds up.
The limits stay in view. Nineteen products carry no attributable certificate, and no certificate can be tied to a purchased lot. No report PB read includes sterility, and one lacks heavy metals. Purity figures are readings of images. PB preserved no copies, so the chain depends on one laboratory host staying up. Shipping and refund terms could not be read anonymously. And a certificate documents a named sample and its reported analyses — it does not independently verify any physical vial.
Readers can inspect the PepLogix profile, search the PepLogix COA records, compare current prices, or visit the official storefront.
Common questions
Is PepLogix legitimate?
PeptideBenchmark does not issue binary legitimacy or product-safety endorsements. We confirmed a public stock-aware catalog with exact standing prices, 74 certificate documents carrying 73 distinct Bioviridian verification codes, and every one of those 73 codes resolving to a document on the laboratory’s own domain on July 30, 2026. Those are meaningful transparency signals, but they do not independently verify any physical vial, and PB could not read the vendor’s shipping or return terms anonymously.
Does PepLogix publish COAs?
Yes, but not where a visitor can easily find them. No PepLogix product description mentions testing, and the vendor’s own certificate index requires an account. The certificates travel as unlabelled documents attached to product listings: PeptideBenchmark recovered 74 distinct uploads carrying 73 distinct certificates during the July 30, 2026 review, without accessing the account-gated index.
Are PepLogix COAs independently verifiable?
Yes, at the document level — not at the vial level. Every certificate prints a Bioviridian Web Verification Code in the form COA#### (PepLogix’s run from COA3671 to COA6238), and the laboratory hosts its own copy under that code at bioviridians.com, behind a public coa-search.html lookup. All 73 distinct codes — covering every one of the 74 uploads — resolved there on July 30, 2026, and a fabricated code returned nothing on the same day, so the check distinguishes a real code from an invented one. Each certificate also names PepLogix on its face, so the attribution is stated by the laboratory rather than inferred by PB. Because no PepLogix certificate carries a lot or batch number, a resolving code confirms the document, never the unit a reader receives.
What discount does PepLogix offer?
One lane only. On July 30, 2026 the storefront showed four per-item sales: KPV capsules $125 to $100, GHK-Cu capsules $150 to $100, TB-500 capsules $150 to $100, and VIP 10 mg $100 to $75. Only the VIP vial sits on the per-mg comparison board; the three capsule items do not. PB found no sitewide percentage, bundle builder, quantity tier, or public code. These are the vendor’s own promotions, PeptideBenchmark has no PepLogix code, and PB earns nothing if a reader uses them.
What are PepLogix shipping and return terms?
PeptideBenchmark could not read them anonymously. An anonymous request to a PepLogix product page redirected to the storefront’s account page during this review, so no shipping cost, delivery service, cutoff, or refund term was captured. PB publishes no PepLogix shipping or returns terms rather than guessing; readers should obtain them from the vendor directly before ordering.
Does PeptideBenchmark have an affiliate relationship with PepLogix?
No. At the time of this review, PeptideBenchmark had no affiliate, coupon, sponsorship, or paid-placement relationship with PepLogix.